Article info
PDFClinical ethics
Commentary
Pre-emptive suicide, precedent autonomy and preclinical Alzheimer disease
- Correspondence to Professor Rebecca Dresser, Schools of Law and Medicine, Washington University, One Brookings Drive, Box 1120, St Louis, MO 63130, USA; dresser{at}wulaw.wustl.edu
Citation
Pre-emptive suicide, precedent autonomy and preclinical Alzheimer disease
Publication history
- Received May 31, 2013
- Accepted June 6, 2013
- First published July 22, 2013.
Online issue publication
April 27, 2016
Article Versions
- Previous version (27 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Other content recommended for you
- Alzheimer disease and pre-emptive suicide
- On the personal utility of Alzheimer’s disease-related biomarker testing in the research context
- Novel drug candidates targeting Alzheimer’s disease: ethical challenges with identifying the relevant patient population
- Moral motivation regarding dementia risk testing among affected persons in Germany and Israel
- Statins and cognitive function
- Retinal imaging in Alzheimer’s disease
- Associations between primary open angle glaucoma, Alzheimer’s disease and vascular dementia: record linkage study
- Oestrogen receptor polymorphisms are an associated risk factor for mild cognitive impairment and Alzheimer disease in women APOE ɛ4 carriers: a case–control study
- Advance decisions in dementia: when the past conflicts with the present
- Meta-analysis of modifiable risk factors for Alzheimer's disease